The effect of TNFandalpha; secreted from macrophages activated by titanium particles on osteogenic activity regulated by WNT/BMP signaling in osteoprogenitor cells

Biomaterials

Volumn 33, Issue 17, 2012, Pages 4251-4263

  Lee, Sang Soo ^a   Sharma, Ashish R ^a   Choi, Byung Soo ^a   Jung, Jun Sub ^a   Chang, Jun Dong ^a   Park, Seonghun ^a,b   Salvati, Eduardo A ^c   Purdue, Edward P ^c   Song, Dong Keun ^a   Nam, Ju Suk ^a  

^a Hallym University   (South Korea)

^b Pusan National University   (South Korea)

^c Hospital for Special Surgery   (United States)

Author keywords

BMP; Osteolysis; Particle; SOST; TNFandalpha; ; WNT

Indexed keywords

BMP; OSTEOLYSIS; SOST; TNFANDALPHA; WNT;

ARTHROPLASTY; BONE; OSTEOBLASTS; PARTICLES (PARTICULATE MATTER); PHOSPHATASES; TITANIUM;

MACROPHAGES;

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN; COLLAGEN; OSTEOCALCIN; SCLEROSTIN; SMALL INTERFERING RNA; TITANIUM; TRANSCRIPTION FACTOR RUNX2; TUMOR NECROSIS FACTOR ALPHA; WNT PROTEIN; AUTACOID; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN 2; CYTOKINE; GLYCOPROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SOST PROTEIN, MOUSE; WNT3A PROTEIN;

ANIMAL CELL; ARTICLE; AUTOCRINE EFFECT; BONE DEVELOPMENT; BONE DISEASE; BONE MARROW CELL; BONE MINERALIZATION; CELL COMMUNICATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; ENZYME ACTIVITY; MACROPHAGE; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; AGED; ANIMAL; CELL DIFFERENTIATION; CULTURE MEDIUM; CYTOLOGY; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; MIDDLE AGED; OSTEOBLAST; SECRETION; STEM CELL; WNT SIGNALING PATHWAY;

AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; ANIMALS; BIOLOGICAL MARKERS; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEINS; CELL DIFFERENTIATION; CULTURE MEDIA, CONDITIONED; CYTOKINES; GENE EXPRESSION REGULATION; GLYCOPROTEINS; HUMANS; INFLAMMATION MEDIATORS; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MIDDLE AGED; NF-KAPPA B; OSTEOBLASTS; OSTEOGENESIS; STEM CELLS; TITANIUM; TUMOR NECROSIS FACTOR-ALPHA; WNT SIGNALING PATHWAY; WNT3A PROTEIN;

EID: 84862780434     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.03.005     Document Type: Article

References (60)

1. Harris W.H. The problem is osteolysis. Clin Orthop Relat Res 1995, 46-53.
2. Friedman R.J., Black J., Galante J.O., Jacobs J.J., Skinner H.B. Current concepts in orthopaedic biomaterials and implant fixation. Instr Course Lect 1994, 43:233-255.
3. Abu-Amer Y., Darwech I., Clohisy J.C. Aseptic loosening of total joint replacements: mechanisms underlying osteolysis and potential therapies. Arthritis Res Ther 2007, 9(Suppl. 1):S6.
4. Purdue P.E., Koulouvaris P., Nestor B.J., Sculco T.P. The central role of wear debris in periprosthetic osteolysis. HSS J 2006, 2:102-113.
5. Horowitz S.M., Gonzales J.B. Inflammatory response to implant particulates in a macrophage/osteoblast coculture model. Calcif Tissue Int 1996, 59:392-396.
6. Gallo J., Raska M., Mrazek F., Petrek M. Bone remodeling, particle disease and individual susceptibility to periprosthetic osteolysis. Physiol Res 2008, 57:339-349.
7. Horowitz S.M., Gonzales J.B. Effects of polyethylene on macrophages. J Orthop Res 1997, 15:50-56.
8. Horowitz S.M., Luchetti W.T., Gonzales J.B., Ritchie C.K. The effects of cobalt chromium upon macrophages. J Biomed Mater Res 1998, 41:468-473.
9. Tanaka Y., Nakayamada S., Okada Y. Osteoblasts and osteoclasts in bone remodeling and inflammation. Curr Drug Targets Inflamm Allergy 2005, 4:325-328.
10. Vermes C., Glant T.T., Hallab N.J., Fritz E.A., Roebuck K.A., Jacobs J.J. The potential role of the osteoblast in the development of periprosthetic osteolysis: review of in vitro osteoblast responses to wear debris, corrosion products, and cytokines and growth factors. J Arthroplasty 2001, 16:95-100.
11. Goldring S.R., Goldring M.B. Eating bone or adding it: the Wnt pathway decides. Nat Med 2007, 13:133-134.
12. Yamaguchi A., Komori T., Suda T. Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs, and Cbfa1. Endocr Rev 2000, 21:393-411.
13. Pinzone J.J., Hall B.M., Thudi N.K., Vonau M., Qiang Y.W., Rosol T.J., et al. The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood 2009, 113:517-525.
14. Gazzerro E., Canalis E. Bone morphogenetic proteins and their antagonists. Rev Endocr Metab Disord 2006, 7:51-65.
15. Mbalaviele G., Sheikh S., Stains J.P., Salazar V.S., Cheng S.L., Chen D., et al. Beta-catenin and BMP-2 synergize to promote osteoblast differentiation and new bone formation. J Cell Biochem 2005, 94:403-418.
16. Diarra D., Stolina M., Polzer K., Zwerina J., Ominsky M.S., Dwyer D., et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007, 13:156-163.
17. Baker-LePain J.C., Nakamura M.C., Lane N.E. Effects of inflammation on bone: an update. Curr Opin Rheumatol 2011, 23:389-395.
18. Buly R.L., Huo M.H., Salvati E., Brien W., Bansal M. Titanium wear debris in failed cemented total hip arthroplasty. An analysis of 71 cases. J Arthroplasty 1992, 7:315-323.
19. Valles G., Gonzalez-Melendi P., Gonzalez-Carrasco J.L., Saldana L., Sanchez-Sabate E., Munuera L., et al. Differential inflammatory macrophage response to rutile and titanium particles. Biomaterials 2006, 27:5199-5211.
20. Valles G., Gonzalez-Melendi P., Saldana L., Rodriguez M., Munuera L., Vilaboa N. Rutile and titanium particles differentially affect the production of osteoblastic local factors. J Biomed Mater Res A 2008, 84:324-336.
21. Lee H.G., Minematsu H., Kim K.O., Celil Aydemir A.B., Shin M.J., Nizami S.A., et al. Actin and ERK1/2-CEBPbeta signaling mediates phagocytosis-induced innate immune response of osteoprogenitor cells. Biomaterials 2011, 32:9197-9206.
22. Valles G., Gil-Garay E., Munuera L., Vilaboa N. Modulation of the cross-talk between macrophages and osteoblasts by titanium-based particles. Biomaterials 2008, 29:2326-2335.
23. Maloney W.J., Smith R.L. Periprosthetic osteolysis in total hip arthroplasty: the role of particulate wear debris. Instr Course Lect 1996, 45:171-182.
24. Hilal G., Martel-Pelletier J., Pelletier J.P., Ranger P., Lajeunesse D. Osteoblast-like cells from human subchondral osteoarthritic bone demonstrate an altered phenotype in vitro: possible role in subchondral bone sclerosis. Arthritis Rheum 1998, 41:891-899.
25. Blum J.S., Li R.H., Mikos A.G., Barry M.A. An optimized method for the chemiluminescent detection of alkaline phosphatase levels during osteodifferentiation by bone morphogenetic protein 2. J Cell Biochem 2001, 80:532-537.
26. Katagiri T., Takahashi N. Regulatory mechanisms of osteoblast and osteoclast differentiation. Oral Dis 2002, 8:147-159.
27. Capdevila J., Izpisua Belmonte J.C. Patterning mechanisms controlling vertebrate limb development. Annu Rev Cell Dev Biol 2001, 17:87-132.
28. Hallab N.J., Jacobs J.J. Biologic effects of implant debris. Bull NYU Hosp Jt Dis 2009, 67:182-188.
29. Hikiji H., Shin W.S., Koizumi T., Takato T., Susami T., Koizumi Y., et al. Peroxynitrite production by TNF-alpha and IL-1beta: implication for suppression of osteoblastic differentiation. Am J Physiol Endocrinol Metab 2000, 278:E1031-E1037.
30. Gilbert L., He X., Farmer P., Boden S., Kozlowski M., Rubin J., et al. Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology 2000, 141:3956-3964.
31. Fellah B.H., Delorme B., Sohier J., Magne D., Hardouin P., Layrolle P. Macrophage and osteoblast responses to biphasic calcium phosphate microparticles. J Biomed Mater Res A 2010, 93:1588-1595.
32. Gerstenfeld L.C., Cho T.J., Kon T., Aizawa T., Cruceta J., Graves B.D., et al. Impaired intramembranous bone formation during bone repair in the absence of tumor necrosis factor-alpha signaling. Cells Tissues Organs 2001, 169:285-294.
33. Oeckinghaus A., Ghosh S. The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol 2009, 1:a000034.
34. Huang H., Zhao N., Xu X., Xu Y., Li S., Zhang J., et al. Dose-specific effects of tumor necrosis factor alpha on osteogenic differentiation of mesenchymal stem cells. Cell Prolif 2011, 44:420-427.
35. Miller J.R. The Wnts. Genome Biol 2002, 3. REVIEWS3001.
36. Wodarz A., Nusse R. Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol 1998, 14:59-88.
37. Canalis E., Economides A.N., Gazzerro E. Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev 2003, 24:218-235.
38. Lintern K.B., Guidato S., Rowe A., Saldanha J.W., Itasaki N. Characterization of wise protein and its molecular mechanism to interact with both Wnt and BMP signals. J Biol Chem 2009, 284:23159-23168.
39. Vincent C., Findlay D.M., Welldon K.J., Wijenayaka A.R., Zheng T.S., Haynes D.R., et al. Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J Bone Miner Res 2009, 24:1434-1449.
40. Yamamoto N., Akiyama S., Katagiri T., Namiki M., Kurokawa T., Suda T. Smad1 and smad5 act downstream of intracellular signalings of BMP-2 that inhibits myogenic differentiation and induces osteoblast differentiation in C2C12 myoblasts. Biochem Biophys Res Commun 1997, 238:574-580.
41. Collette N.M., Genetos D.C., Murugesh D., Harland R.M., Loots G.G. Genetic evidence that SOST inhibits WNT signaling in the limb. Dev Biol 2010, 342:169-179.
42. Kusu N., Laurikkala J., Imanishi M., Usui H., Konishi M., Miyake A., et al. Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J Biol Chem 2003, 278:24113-24117.
43. Tuan R.S., Lee F.Y., Y T.K., Wilkinson J.M., Smith R.L. What are the local and systemic biologic reactions and mediators to wear debris, and what host factors determine or modulate the biologic response to wear particles?. J Am Acad Orthop Surg 2008, 16(Suppl. 1):S42-S48.
44. Seo S.W., Lee D., Cho S.K., Kim A.D., Minematsu H., Celil Aydemir A.B., et al. ERK signaling regulates macrophage colony-stimulating factor expression induced by titanium particles in MC3T3.E1 murine calvarial preosteoblastic cells. Ann N Y Acad Sci 2007, 1117:151-158.
45. Sun D.H., Trindade M.C., Nakashima Y., Maloney W.J., Goodman S.B., Schurman D.J., et al. Human serum opsonization of orthopedic biomaterial particles: protein-binding and monocyte/macrophage activation in vitro. J Biomed Mater Res A 2003, 65:290-298.
46. Franchimont N., Wertz S., Malaise M. Interleukin-6: an osteotropic factor influencing bone formation?. Bone 2005, 37:601-606.
47. Lisignoli G., Cristino S., Toneguzzi S., Grassi F., Piacentini A., Cavallo C., et al. IL1beta and TNFalpha differently modulate CXCL13 chemokine in stromal cells and osteoblasts isolated from osteoarthritis patients: evidence of changes associated to cell maturation. Exp Gerontol 2004, 39:659-665.
48. Scott D.L., Kingsley G.H. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006, 355:704-712.
49. Ammann P., Rizzoli R., Bonjour J.P., Bourrin S., Meyer J.M., Vassalli P., et al. Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. J Clin Invest 1997, 99:1699-1703.
50. Micheau O., Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003, 114:181-190.
51. Gilbert L.C., Rubin J., Nanes M.S. The p55 TNF receptor mediates TNF inhibition of osteoblast differentiation independently of apoptosis. Am J Physiol Endocrinol Metab 2005, 288:E1011-E1018.
52. Shimada K., Ikeda K., Ito K. Traf2 interacts with Smad4 and regulates BMP signaling pathway in MC3T3-E1 osteoblasts. Biochem Biophys Res Commun 2009, 390:775-779.
53. Heiland G.R., Zwerina K., Baum W., Kireva T., Distler J.H., Grisanti M., et al. Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann Rheum Dis 2010, 69:2152-2159.
54. Harada S., Rodan G.A. Control of osteoblast function and regulation of bone mass. Nature 2003, 423:349-355.
55. Poole K.E., van Bezooijen R.L., Loveridge N., Hamersma H., Papapoulos S.E., Lowik C.W., et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 2005, 19:1842-1844.
56. Stewart K., Walsh S., Screen J., Jefferiss C.M., Chainey J., Jordan G.R., et al. Further characterization of cells expressing STRO-1 in cultures of adult human bone marrow stromal cells. J Bone Miner Res 1999, 14:1345-1356.
57. Quarles L.D., Yohay D.A., Lever L.W., Caton R., Wenstrup R.J. Distinct proliferative and differentiated stages of murine MC3T3-E1 cells in culture: an in vitro model of osteoblast development. J Bone Miner Res 1992, 7:683-692.
58. Winkler D.G., Sutherland M.K., Geoghegan J.C., Yu C., Hayes T., Skonier J.E., et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 2003, 22:6267-6276.
59. Krause C., Korchynskyi O., de Rooij K., Weidauer S.E., de Gorter D.J., van Bezooijen R.L., et al. Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways. J Biol Chem 2010, 285:41614-41626.
60. Singhatanadgit W., Salih V., Olsen I. Bone morphogenetic protein receptors and bone morphogenetic protein signaling are controlled by tumor necrosis factor-alpha in human bone cells. Int J Biochem Cell Biol 2006, 38:1794-1807.